Please login to the form below

Not currently logged in
Email:
Password:

Jetrea

This page shows the latest Jetrea news and features for those working in and with pharma, biotech and healthcare.

Novartis' Lucentis wins fourth NICE recommendation

Novartis' Lucentis wins fourth NICE recommendation

The NICE recommendation is the second in the space of a week for Novartis, which two days ago received a green light for Jetrea (ocriplasmin) to treat patients with the rare

Latest news

  • NICE backs Novartis/ ThromboGenics’ eye drug NICE backs Novartis/ ThromboGenics’ eye drug

    Novartis' eyecare ambitions in the UK continued apace as authorities backed the Swiss pharma company's drug Jetrea in final guidance. ... NICE's recommendation limits use of Jetrea compared to its European approval, which covers all vitreomacular

  • NICE backs Novartis' Jetrea in rare eye condition NICE backs Novartis' Jetrea in rare eye condition

    NICE backs Novartis' Jetrea in rare eye condition. Recommends drug be available for NHS use to treat vitreomacular traction. ... This differs from its licence from the European Medicines Agency (EMA), which in March 2013 approved the use of Jetrea in

  • Alcon wins initial NICE backing for Jetrea in rare eye condition Alcon wins initial NICE backing for Jetrea in rare eye condition

    It purchased the rights to commercialise Jetrea outside the US from its developers ThromboGenics in 2012 as part of a deal potentially worth up to 375m. ... In addition to its European licence, Jetrea won approval in October last year for the treatment

  • Novartis, ThromboGenics' eye drug Jetrea gets green light in EU Novartis, ThromboGenics' eye drug Jetrea gets green light in EU

    Novartis, ThromboGenics' eye drug Jetrea gets green light in EU. First drug specifically approved for vitreomacular adhesion. ... Novartis has bolstered its ophthalmology portfolio in the EU after winning approval for Jetrea, the first drug specifically

  • Novartis' eye drug Jetrea recommended for EU approval Novartis' eye drug Jetrea recommended for EU approval

    European regulatory authorities have backed Novartis' licence application for its new eye drug Jetrea (ocriplasmin). ... world.". Jetrea is a recombinant form of human protein (plasmin) that is administered through a one-time, single intravitreal

More from news
Approximately 5 fully matching, plus 3 partially matching documents found.

Latest appointments

  • ThromboGenics bolsters leadership team ThromboGenics bolsters leadership team

    Vangeersdaele will be leading and developing the overall commercial strategy for the company’s recently formed Jetrea business unit, which was created following ThromboGenics regaining full rights to Jetrea from Novartis. ... I am convinced that their

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics